Skip to main content
TipRanks
Go Ultimate75% OFF

Vaccinex (VCNX) AI Stock Analysis

304 Followers
VCNX

Vaccinex

(Other OTC:VCNX)

Select Model
Rating:48.5Neutral
Price Target:$0.89â–¼(-8.32% Downside)
Action:reiterated
Date:11/20/26

The overall score of 48.5 reflects a high-risk, speculative biotechnology company. The most significant factor is the extremely weak balance sheet with negative equity and high leverage, which poses a going-concern risk. Partially offsetting this are improving operational trends, including strong revenue growth and narrowing losses, and moderately bullish short-term technical momentum. However, the company remains unprofitable with negative cash flows, and the stock's longer-term technical trend is bearish. The score is constrained by the precarious financial state.

Positive Factors
Revenue GrowthThe sharp 2025 revenue increase indicates stronger activity around the company’s development and collaboration base. Although the revenue level remains modest, sustained growth could improve funding capacity and support continued advancement of its clinical programs.
Negative Factors
Persistent Net LossesPersistent net losses show that the company’s current revenue base is not sufficient to cover operating and development costs. Continued losses may restrict internal investment capacity and increase reliance on external financing or partnering proceeds to advance the pipeline.

Vaccinex (VCNX) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%125%VCNX+39.14%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.41M
Dividend Yield
―
Average Volume (3M)
1,535
Price to Earnings (P/E)
-0.5
Beta (1Y)
1.83
Revenue Growth
―
EPS Growth
―
Country
US
Employees
25
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Vaccinex Business Overview & Revenue Model

Company Description

Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate trea...

How the Company Makes Money

Vaccinex has historically not had meaningful recurring revenue from product sales because it has not broadly commercialized an approved therapeutic product. As a clinical-stage biotech, its funding and any revenue have typically been driven by (1) co...

Vaccinex Financial Statement Overview

Summary

Financial performance is weak but improving. Revenue grew 249% to $2.1M with 98% gross margins, and net losses narrowed to -$5.3M. However, the balance sheet is critically distressed with -$7.6M equity and debt exceeding assets, while cash flow remains negative. The overall financial health is fragile and high-risk.

Income Statement

30Negative

Balance Sheet

10Very Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue601.00K2.10M601.00K570.00K100.00K900.00K
Gross Profit574.00K2.06M601.00K570.00K68.00K731.00K
EBITDA-18.51M-5.20M-18.54M-19.75M-19.61M-21.40M
Net Income-18.63M-5.26M-18.63M-20.25M-19.72M-22.38M
Balance Sheet
Total Assets2.60M1.80M2.60M3.63M7.98M9.84M
Cash, Cash Equivalents and Short-Term Investments1.11M140.00K1.11M1.53M6.39M8.59M
Total Debt25.00K5.52M25.00K247.00K485.00K390.00K
Total Liabilities5.08M9.39M5.08M5.94M2.78M2.43M
Stockholders Equity-2.49M-7.59M-2.49M-2.31M5.19M7.41M
Cash Flow
Free Cash Flow-16.21M-6.46M-16.21M-17.30M-19.17M-25.33M
Operating Cash Flow-16.19M-6.45M-16.19M-17.23M-19.07M-25.30M
Investing Cash Flow-22.00K-9,000-22.00K-67.00K-99.00K-32.00K
Financing Cash Flow15.78M5.49M15.78M12.45M16.98M23.32M

Vaccinex Technical Analysis

Technical Analysis SentimentNegative
Last Price0.97

Price Trends

50DMA0.96Negative
100DMA1.00Negative
200DMA1.01Negative

Market Momentum

MACD0.02Negative
RSI46.53Neutral
STOCH77.54Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Negative. The current price of 0.97 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.96, and below the 200-day MA of 1.01, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 77.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCNX.

Vaccinex Risk Analysis

Vaccinex disclosed 49 risk factors in its most recent earnings report. Vaccinex reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.The Series A Preferred Stock ranks senior to the Company's common stock with respect to rights on the distribution of assets upon liquidation, dissolution and winding up.Q3, 2024
2.Shares of common stock issuable upon conversion of our Series A Preferred Stock will be dilutive to our existing shareholders upon conversion and adversely affect the market price of our common stock.Q3, 2024
3.The Alzheimer's Drug Discovery Foundation may be able to sell shares of our common stock in the public market, which may cause the market price of our common stock to decrease, and therefore make it more difficult to raise equity financing or issue equity as consideration in an acquisition.Q3, 2024

Vaccinex Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VCNX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
VCNXVCNX49Neutral$2.41M-0.49104.38%―――
AZTRAZTR44Neutral$3.22M-0.08-191.57%――87.93%
REVBREVB41Neutral$2.52M-0.09-124.23%――94.95%
GTBPGTBP40Underperform$6.80M-0.02-548.33%――60.31%
TOVXTOVX31Underperform$5.87M-0.48-64.99%――95.48%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%VCNXTOVXGTBPREVBCEROAZTRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VCNX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VCNXVaccinex0.970.2943.24%
TOVXTheriva Biologics, Inc.0.12-0.11-47.83%
GTBPGt Biopharma, Inc.2.96-16.07-84.45%
REVBRevelation Biosciences Inc.3.50-20.31-85.30%
CEROCero Therapeutics Holdings, Inc.0.01-0.06-85.07%
AZTRAzitra Inc0.52-2.71-84.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026